Evolving concepts in the pathogenesis of uraemic cardiomyopathy

X Wang, JI Shapiro - Nature Reviews Nephrology, 2019 - nature.com
Nature Reviews Nephrology, 2019nature.com
The term uraemic cardiomyopathy refers to the cardiac abnormalities that are seen in
patients with chronic kidney disease (CKD). Historically, this term was used to describe a
severe cardiomyopathy that was associated with end-stage renal disease and characterized
by severe functional abnormalities that could be reversed following renal transplantation. In
a modern context, uraemic cardiomyopathy describes the clinical phenotype of cardiac
disease that accompanies CKD and is perhaps best characterized as diastolic dysfunction …
Abstract
The term uraemic cardiomyopathy refers to the cardiac abnormalities that are seen in patients with chronic kidney disease (CKD). Historically, this term was used to describe a severe cardiomyopathy that was associated with end-stage renal disease and characterized by severe functional abnormalities that could be reversed following renal transplantation. In a modern context, uraemic cardiomyopathy describes the clinical phenotype of cardiac disease that accompanies CKD and is perhaps best characterized as diastolic dysfunction seen in conjunction with left ventricular hypertrophy and fibrosis. A multitude of factors may contribute to the pathogenesis of uraemic cardiomyopathy, and current treatments only modestly improve outcomes. In this Review, we focus on evolving concepts regarding the roles of fibroblast growth factor 23 (FGF23), inflammation and systemic oxidant stress and their interactions with more established mechanisms such as pressure and volume overload resulting from hypertension and anaemia, respectively, activation of the renin–angiotensin and sympathetic nervous systems, activation of the transforming growth factor-β (TGFβ) pathway, abnormal mineral metabolism and increased levels of endogenous cardiotonic steroids.
nature.com